Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly (NYSE: LLY) announced its third-quarter 2026 dividend. The board declared a cash dividend of $1.73 per share on outstanding common stock.
The dividend will be paid on September 10, 2026, to shareholders of record as of August 14, 2026.
Lilly (NYSE: LLY) reported Phase 3 BRUIN CLL-322 results in relapsed or refractory CLL/SLL. Adding Jaypirca (pirtobrutinib) to venetoclax plus rituximab cut the risk of disease progression or death by 45% (HR=0.55; p=0.0001).
Among 639 patients (79.8% BTK-pretreated), median PFS was not reached with the triple regimen versus 39.7 months for control. Time to next treatment favored Jaypirca (HR=0.50). Overall survival data are immature. Safety was broadly consistent with known profiles, with similar Grade ≥3 AE and discontinuation rates.
Lilly (NYSE: LLY) reported initial Phase 1 AJX-101 data for its first-in-class type II JAK2 inhibitor AJ1-11095 in previously treated myelofibrosis, to be presented at the 2026 EHA Annual Meeting.
Results show high rates of spleen volume reduction, symptom improvement, VAF decreases, and a generally manageable safety profile.
Eli Lilly (NYSE: LLY) launched a national Watch This campaign with Shaquille O'Neal, highlighting that his long-standing symptoms were moderate obstructive sleep apnea (OSA) treated with Zepbound (tirzepatide).
Zepbound is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity, used with diet and exercise, and showed significant 52-week reductions in breathing interruptions and symptom remission in clinical studies.
Eli Lilly (NYSE: LLY) received FDA approval for an every-eight-week maintenance dosing regimen of EBGLYSS (lebrikizumab-lbkz) for adults and adolescents (≥12 years, ≥40 kg) with moderate-to-severe atopic dermatitis.
The single 250 mg/2 mL subcutaneous injection allows as few as six maintenance doses per year without required prescription topicals from treatment start, supported by Phase 3 ADjoin extension data and exposure-response modeling.
Convatec and the Lilly Foundation, supported by Eli Lilly (NYSE:LLY), committed c.$5 million to Partners In Health (PIH) to strengthen care for non‑communicable and chronic conditions in resource‑limited settings.
The funding supports community health workers, training, diagnosis, referral pathways, and academic collaboration in countries including Rwanda, Peru, Malawi and Sierra Leone, honoring former Convatec CEO Karim Bitar’s legacy.
Lilly (NYSE: LLY) reported Phase 3 ACHIEVE data for oral GLP-1 Foundayo (orforglipron) in type 2 diabetes. Foundayo achieved larger A1C reductions and greater weight loss than oral semaglutide, dapagliflozin and placebo, with up to 2.2% A1C drops and 19.7 lbs weight loss.
Lilly plans a U.S. FDA submission for type 2 diabetes by the end of the second quarter, using a National Priority Review Voucher. According to Lilly, cardiovascular risk markers and safety were consistent with prior studies, with mainly gastrointestinal side effects.
Eli Lilly (NYSE: LLY) reported post-hoc results from ATTAIN-1 and ATTAIN-2 showing that women with obesity or overweight taking the highest dose of Foundayo (orforglipron), an oral GLP-1 taken without food or water restrictions, had significant weight loss at all menopause stages over 72 weeks.
Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28.2 lbs (14.1%) post-menopause in ATTAIN-1, and up to 27.8 lbs (13.6%) post-menopause in ATTAIN-2, with notable reductions in waist circumference and high proportions achieving ≥15% weight loss.
Lilly (NYSE:LLY) reported Phase 3 data for investigational triple agonist retatrutide in obesity, type 2 diabetes, knee osteoarthritis pain, and obstructive sleep apnea.
Across TRIUMPH-1 and TRANSCEND-T2D-1, retatrutide produced large average weight losses (up to 28.3%), A1C reductions up to 2.0%, and broad cardiometabolic risk-factor improvements, with gastrointestinal side effects common but mostly mild to moderate.
Lilly (NYSE: LLY) will highlight its expanding hematology portfolio at the 2026 European Hematology Association (EHA) Annual Meeting in Stockholm, June 11-14.
Key presentations cover Phase 3 BRUIN CLL-322 data for Jaypirca in relapsed/refractory CLL/SLL, plus early-stage programs from Ajax Therapeutics and Kelonia Therapeutics, which Lilly has agreed to acquire.